You searched for "ESCRS"
Biotech Healthcare Successfully Concludes Global Phakic Users Meeting 2024 in Barcelona
14 October 2024
|
Company Profiles, Awards, Conferences & Anniversaries
October 3, 2024 – Celebrating its 25th anniversary, Biotech Healthcare hosted the Global Phakic Users Meeting 2024 at the stunning Joan Miró Foundation in Barcelona on 5th September. Bringing together over 150 ophthalmologists from 28 countries, the event showcased Biotech's...
Patients “didn’t realise they had choice in receiving care,” finds new report on patient choice in elective eyecare
The current system of elective care is struggling to inform patients of their rights to choose healthcare providers and procedures, and offering little information or support when decisions need to be made, according to a new report. The report, Patient...Principles of management
Whatever section of pathology is to blame and wherever it strikes, the aim of treatment is always the same. Find the cause if you can. Establish the effects of the cause. Halt the pathological process if you can. Reverse its...What's trending Jun/Jul 2020
Here in the UK, we’ve been in lockdown since 23 March 2020, with much of the rest of the world entering degrees of lockdown since February-March 2020. COVID-19 has dominated the headlines and social media, so without further ado, I...What's trending Dec/Jan 2022
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #eyetrackingtechnology #assitivetechnology #gaming Modern eye trackers often rely on electronic specialist hardware that continuously scan the the pupil and reflections from...My top five ways in which LinkedIn can be useful for ophthalmologists
3 April 2023
| Umar Ahmed
|
EYE - General
LinkedIn is the world’s largest professional social networking site, that allows over 830 million users from over 200 countries from a variety of industries to connect. As a result, it is a powerful tool used by professionals to network, collaborate,...
My Top Five: Ways in which LinkedIn can be useful for ophthalmologists
3 April 2023
| Umar Ahmed
|
EYE - General
LinkedIn is the world’s largest professional social networking site, that allows over 830 million users from over 200 countries from a variety of industries to connect. As a result, it is a powerful tool used by professionals to network, collaborate,...
Just sign here: the intricacies of consent in the post-Montgomery era
1 February 2018
|
EYE - General
The consent process is a vital part of the patient pathway and is far more than just getting the patient to sign on the dotted line. In my work in litigation I often see issues around informed consent resulting in...
Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment
Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...Blind Faith: In Conversation with Mariya Moosajee
16 August 2023
|
EYE - General
In light of the BBC releasing Blind Faith: Do genetic eye disease ‘treatments' work? earlier this year, a documentary which follows BBC journalist Ramadan Younes as he investigates practitioners who falsely claim to have ‘treatments’ for genetic eye disease, Eye...
SOS (Simplified Ophthalmic Statistics) Part 2: How to summarise your data and why it’s a good idea to do so
1 August 2018
| Catey Bunce
|
EYE - General
Studies involve capturing data. Statistical techniques allow data to be used to answer important research questions. A case series may have data on a handful of subjects but we are now entering the Big Data arena where datasets can be...
Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
1 February 2015
| Pearse A Keane (Prof), Adnan Tufail
|
EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
